Search

Your search keyword '"Sofie Demeyer"' showing total 10 results
Start Over Author "Sofie Demeyer" Publisher american association for cancer research (aacr)
10 results on '"Sofie Demeyer"'

1. Supplemental tables and figures from HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development

Author

Jan Cools, Enrico Radaelli, Olli Lohi, Maria Bouvy-Liivrand, Susanna Teppo, Merja Heinäniemi, Jules P. Meijerink, Jean Soulier, Rik Gijsbers, Simon Bornschein, Ellen Geerdens, Antonis Dagklis, Marlies Vanden Bempt, Carmen Vicente, Roel Vandepoel, Olga Gielen, Bram Sweron, Delphine Verbeke, Sandrine Degryse, Sofie Demeyer, and Charles E. de Bock

Abstract

Supplemental tables and figures

Published
2023
Full Text
View/download PDF

2. supplementary table S3 from HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development

Author

Jan Cools, Enrico Radaelli, Olli Lohi, Maria Bouvy-Liivrand, Susanna Teppo, Merja Heinäniemi, Jules P. Meijerink, Jean Soulier, Rik Gijsbers, Simon Bornschein, Ellen Geerdens, Antonis Dagklis, Marlies Vanden Bempt, Carmen Vicente, Roel Vandepoel, Olga Gielen, Bram Sweron, Delphine Verbeke, Sandrine Degryse, Sofie Demeyer, and Charles E. de Bock

Abstract

supplementary table (excel)

Published
2023
Full Text
View/download PDF

3. supplementary table S2 from HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development

Author

Jan Cools, Enrico Radaelli, Olli Lohi, Maria Bouvy-Liivrand, Susanna Teppo, Merja Heinäniemi, Jules P. Meijerink, Jean Soulier, Rik Gijsbers, Simon Bornschein, Ellen Geerdens, Antonis Dagklis, Marlies Vanden Bempt, Carmen Vicente, Roel Vandepoel, Olga Gielen, Bram Sweron, Delphine Verbeke, Sandrine Degryse, Sofie Demeyer, and Charles E. de Bock

Abstract

supplementary table (excel)

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 2 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia

Author

Jan Cools, Heidi Segers, Johan Maertens, Kim De Keersmaecker, Nancy Boeckx, Anne Uyttebroeck, Bronte Manouk Verhoeven, Nicole Mentens, Kris Jacobs, Olga Gielen, Jolien De Bie, Charles E. de Bock, Cristina Prieto, Sofie Demeyer, and Delphine Verbeke

Abstract

Suppl. figure 2: PDX samples have different basal NR3C1 expression levels.

Published
2023
Full Text
View/download PDF

6. Data from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia

Author

Jan Cools, Heidi Segers, Johan Maertens, Kim De Keersmaecker, Nancy Boeckx, Anne Uyttebroeck, Bronte Manouk Verhoeven, Nicole Mentens, Kris Jacobs, Olga Gielen, Jolien De Bie, Charles E. de Bock, Cristina Prieto, Sofie Demeyer, and Delphine Verbeke

Abstract

Purpose:KPT-8602 (Eltanexor) is a second-generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in preclinical models and with minimal effects on normal cells. In this study, we evaluated whether KPT-8602 would synergize with dexamethasone, vincristine, or doxorubicin, three drugs currently used for the treatment of ALL.Experimental Design:First, we searched for the most synergistic combination of KPT-8602 with dexamethasone, vincristine, or doxorubicin in vitro in both B-ALL and T-ALL cell lines using proliferation and apoptosis as a readout. Next, we validated this synergistic effect by treatment of clinically relevant B- and T-ALL patient-derived xenograft models in vivo. Finally, we performed RNA-sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) to determine the mechanism of synergy.Results:KPT-8602 showed strong synergism with dexamethasone on human B-ALL and T-ALL cell lines as well as in vivo in three patient-derived ALL xenografts. Compared with single-drug treatment, the drug combination caused increased apoptosis and led to histone depletion. Mechanistically, integration of ChIP-seq and RNA-seq data revealed that addition of KPT-8602 to dexamethasone enhanced the activity of the glucocorticoid receptor (NR3C1) and led to increased inhibition of E2F-mediated transcription. We observed strong inhibition of E2F target genes related to cell cycle, DNA replication, and transcriptional regulation.Conclusions:Our preclinical study demonstrates that KPT-8602 enhances the effects of dexamethasone to inhibit B-ALL and T-ALL cells via NR3C1- and E2F-mediated transcriptional complexes, allowing to achieve increased dexamethasone effects for patients.

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 1 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia

Author

Jan Cools, Heidi Segers, Johan Maertens, Kim De Keersmaecker, Nancy Boeckx, Anne Uyttebroeck, Bronte Manouk Verhoeven, Nicole Mentens, Kris Jacobs, Olga Gielen, Jolien De Bie, Charles E. de Bock, Cristina Prieto, Sofie Demeyer, and Delphine Verbeke

Abstract

Suppl. figure 1: Doxorubicin and vincristine are not synergistic with KPT-8602 in diminishing proliferation of B-ALL and T-ALL

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia

Author

Jan Cools, Heidi Segers, Johan Maertens, Kim De Keersmaecker, Nancy Boeckx, Anne Uyttebroeck, Bronte Manouk Verhoeven, Nicole Mentens, Kris Jacobs, Olga Gielen, Jolien De Bie, Charles E. de Bock, Cristina Prieto, Sofie Demeyer, and Delphine Verbeke

Abstract

Suppl. figure 4: KPT-8602 single treatment or combined treatment with dexamethasone does not lead to nuclear accumulation of IKBα nor to effects on NFκB target genes

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 3 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia

Author

Jan Cools, Heidi Segers, Johan Maertens, Kim De Keersmaecker, Nancy Boeckx, Anne Uyttebroeck, Bronte Manouk Verhoeven, Nicole Mentens, Kris Jacobs, Olga Gielen, Jolien De Bie, Charles E. de Bock, Cristina Prieto, Sofie Demeyer, and Delphine Verbeke

Abstract

Suppl. figure 3: Dexamethasone and dexamethasone+KPT-8602 treatment induce NR3C1 binding and leads to differential gene expression of the bound genes in the SUP-T1 cell line

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results